Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Sirolimus and Oseltamivir for Treatment of Influenza
NCT03901001Phase 3Active, not recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- May 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sirolimus in influenza (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Normalization of respiratory status at 28 days. Started May 2023; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03901001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03901001.